China’s Simnova Bags USD59.5 Million in New Funding to Advance Off-the-Shelf Cell Therapies
Simnova Biotech has secured nearly CNY400 million (USD59.5 million) in its latest funding round to accelerate clinical research of the Chinese cell therapy startup’s off-the-shelf cell therapies, the firm said today. The Series B funding round was co-led by Shanghai state-owned investment funds Fortera Capital and Pudong Venture Capital, along with private equity firm Cenova Ventures, Shanghai-based Simnova said. Suzhou state-owned investment firm Oriza Holdings participated as a follow-on investor, while existing shareholder Youshan Capital increased its investment.
Share:
More News
“Fast Track designation in lung cancer represents an important milestone for TRE-515 and further validates our strategy of combining dCK inhibition with targeted cancer therapies,” said Dr. Ken Schultz, Trethera Chairman and CEO. “KRAS G12C inhibitors have transformed the NSCLC treatment landscape, but resistance and incomplete responses remain major challenges.
“AvenCell has built a differentiated cell therapy platform that brings together CRISPR-engineered allogeneic CAR-T technology with a unique switchable CAR approach designed to provide greater control over CAR-T activity,” said Todd Davis, CEO of Ligand. “We believe the combination of these technologies, together with the encouraging clinical data generated to
“Advanced gastric cancer is characterized by substantial biological and clinical heterogeneity. Previous studies have shown that the magnitude of benefit from PD-1 inhibitor therapy is closely associated with PD-L1 expression, and that there remains room to further improve outcomes, particularly in patients with low PD-L1 expression. How to broaden the
“The evERA results represent an important step forward for people with ER-positive advanced breast cancer and underscore the potential for giredestrant to help address the challenge of disease progression in this setting,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “Together with the